$1 Trillion in Medicaid Cuts: What Pharma Teams Need to Understand

Medicaid cuts are one part of a larger economic shift reshaping how health systems evaluate financial risk, payer mix exposure, and whether therapies move from approval to actual utilization.

Most access discussions that stall after clinical endorsement do so for economic reasons that are rarely stated openly by health system leaders.

This analysis examines how those decisions are being made today and what brand and market access leaders need to do differently as a result.

We will contact you with more information.